557 related articles for article (PubMed ID: 21145284)
1. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
Cuzick J; Sestak I; Pinder SE; Ellis IO; Forsyth S; Bundred NJ; Forbes JF; Bishop H; Fentiman IS; George WD
Lancet Oncol; 2011 Jan; 12(1):21-9. PubMed ID: 21145284
[TBL] [Abstract][Full Text] [Related]
2. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.
Houghton J; George WD; Cuzick J; Duggan C; Fentiman IS; Spittle M; ; ;
Lancet; 2003 Jul; 362(9378):95-102. PubMed ID: 12867108
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials.
Petrelli F; Barni S
Radiother Oncol; 2011 Aug; 100(2):195-9. PubMed ID: 21411161
[TBL] [Abstract][Full Text] [Related]
5. Postoperative tamoxifen for ductal carcinoma in situ.
Staley H; McCallum I; Bruce J
Cochrane Database Syst Rev; 2012 Oct; 10():CD007847. PubMed ID: 23076938
[TBL] [Abstract][Full Text] [Related]
6. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.
Fisher B; Land S; Mamounas E; Dignam J; Fisher ER; Wolmark N
Semin Oncol; 2001 Aug; 28(4):400-18. PubMed ID: 11498833
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
[TBL] [Abstract][Full Text] [Related]
8. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
Guerrieri-Gonzaga A; Sestak I; Lazzeroni M; Serrano D; Rotmensz N; Cazzaniga M; Varricchio C; Pruneri G; Leonardi MC; Orecchia R; Galimberti V; Bonanni B; DeCensi A
Int J Cancer; 2016 Nov; 139(9):2127-34. PubMed ID: 27381855
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
[TBL] [Abstract][Full Text] [Related]
10. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).
Kuo SH; Tseng LM; Chen ST; Sagara Y; Chang YC; Yeh HT; Kuo YL; Hung CC; Lu TP; Lee YH; Toi M; Huang CS
BMC Cancer; 2023 Sep; 23(1):865. PubMed ID: 37710198
[TBL] [Abstract][Full Text] [Related]
12. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis.
Staley H; McCallum I; Bruce J
Breast; 2014 Oct; 23(5):546-51. PubMed ID: 25023044
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Cuzick J; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A; Forbes JF;
Lancet Oncol; 2015 Jan; 16(1):67-75. PubMed ID: 25497694
[TBL] [Abstract][Full Text] [Related]
14. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
Lazzeroni M; Puntoni M; Guerrieri-Gonzaga A; Serrano D; Boni L; Buttiron Webber T; Fava M; Briata IM; Giordano L; Digennaro M; Cortesi L; Falcini F; Serra P; Avino F; Millo F; Cagossi K; Gallerani E; De Simone A; Cariello A; Aprile G; Renne M; Bonanni B; DeCensi A
J Clin Oncol; 2023 Jun; 41(17):3116-3121. PubMed ID: 36917758
[TBL] [Abstract][Full Text] [Related]
15. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Haviland JS; Owen JR; Dewar JA; Agrawal RK; Barrett J; Barrett-Lee PJ; Dobbs HJ; Hopwood P; Lawton PA; Magee BJ; Mills J; Simmons S; Sydenham MA; Venables K; Bliss JM; Yarnold JR;
Lancet Oncol; 2013 Oct; 14(11):1086-1094. PubMed ID: 24055415
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
Julien JP; Bijker N; Fentiman IS; Peterse JL; Delledonne V; Rouanet P; Avril A; Sylvester R; Mignolet F; Bartelink H; Van Dongen JA
Lancet; 2000 Feb; 355(9203):528-33. PubMed ID: 10683002
[TBL] [Abstract][Full Text] [Related]
17. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
McCormick B; Winter KA; Woodward W; Kuerer HM; Sneige N; Rakovitch E; Smith BL; Germain I; Hartford AC; O'Rourke MA; Walker EM; Strom EA; Hopkins JO; Pierce LJ; Pu AT; Sumida KNM; Vesprini D; Moughan J; White JR
J Clin Oncol; 2021 Nov; 39(32):3574-3582. PubMed ID: 34406870
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Stockholm Breast Cancer Study Group.
Dalberg K; Johansson H; Johansson U; Rutqvist LE
Cancer; 1998 Jun; 82(11):2204-11. PubMed ID: 9610700
[TBL] [Abstract][Full Text] [Related]
20. Assessment of treatment for patients with primary ductal carcinoma in situ in the breast.
Fish EB; Chapman JA; Miller NA; Link MA; Fishell E; Wright B; McCready DR; Hiraki GY; Ross TM; Hanna WM; Lickley HL
Ann Surg Oncol; 1998 Dec; 5(8):724-32. PubMed ID: 9869520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
